Quick Links

Contact Us

The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general populat

Authors: Robert A Kloner|||Eric Stanek|||Karishma Desai|||Christopher L Crowe|||Kathryn Paige Ball|||Aaron Haynes|||Raymond C Rosen

Journal: Clinical cardiology

Publication Type: Observational Study

Date: 2024

DOI: PMC10878497

ID: 38377018

Affiliations:

Affiliations

    Huntington Medical Research Institutes, Pasadena, California, USA.|||Elevance Health Inc., Indianapolis, Indiana, USA.|||Carelon Research Inc., Wilmington, Delaware, USA.|||Carelon Research Inc., Wilmington, Delaware, USA.|||Carelon Research Inc., Wilmington, Delaware, USA.|||Carelon Research Inc., Wilmington, Delaware, USA.|||Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California, USA.

Abstract

Tadalafil is a long-acting phosphodiesterase-5 inhibitor (PDE-5i) indicated for erectile dysfunction (ED).

Chemical List

    Tadalafil|||Carbolines|||Phosphodiesterase 5 Inhibitors

Reference List

    Kloner RA, Stanek E, Crowe CL, et al. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: a retrospective, observational study based on healthcare claims and national death index data. J Sex Med. 2023;20:38‐48.|||Anderson SG, Hutchings DC, Woodward M, et al. Phosphodiesterase type‐5 inhibitor use in type 2 diabetes is associated with a reduction in all‐cause mortality. Heart. 2016;102:1750‐1756.|||Andersson DP, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann MJ. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103:1264‐1270.|||Andersson DP, Landucci L, Lagerros YT, et al. Association of phosphodiesterase−5 inhibitors versus alprostadil with survival in men with coronary artery disease. J Am Coll Cardiol. 2021;77:1535‐1550.|||Hackett G, Jones PW, Strange RC, Ramachandran S. Statin, testosterone and phosphodiesterase 5‐inhibitor treatments and age related mortality in diabetes. World J Diabetes. 2017;8:104‐111.|||Wilton KM, Achenbach SJ, Davis 3rd, JM , Myasoedova E, Matteson EL, Crowson CS. Erectile dysfunction and cardiovascular risk in men with rheumatoid arthritis: a population‐based cohort study. J Rheumatol. 2021;48:1641‐1647.|||Vestergaard N, Søgaard P, Torp‐Pedersen C, Aasbjerg K. Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: a nationwide cohort study. Eur J Preventive Cardiol. 2017;24:1498‐1505.|||MacMahon B. The national death index. Am J Public Health. 1983;73:1247‐1248. 10.2105/ajph.73.11.1247